UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2022
Commission File Number 001-15170
GSK plc
(Translation of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
GSK plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Ms E Walmsley | |||
| b) | Position/status | Chief Executive Officer | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£13.2260 | 729 | ||||
£13.2260 | 607 | ||||
£13.2260 | 908 | ||||
| d) | Aggregated information | ||||
Aggregated volume Price | 2,244 £13.2260 | ||||
| e) | Date of the transaction | 2022-10-10 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr I Mackay | |||
| b) | Position/status | Chief Financial Officer | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £13.2260 | 492 | ||||
| £13.2260 | 420 | ||||
| £13.2260 | 628 | ||||
| d) | Aggregated information | ||||
Aggregated volume Price | 1,540 £13.2260 | ||||
| e) | Date of the transaction | 2022-10-10 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Dr H Barron | |||
| b) | Position/status | Non-Executive Director | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 | |||
| b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 6 October 2022 on ADSs held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $30.0000 | 418 | ||||
$30.0000 | 316 | ||||
$30.0000 | 500 | ||||
| d) | Aggregated information | ||||
Aggregated volume Price | 1,234 $30.0000 | ||||
| e) | Date of the transaction | 2022-10-10 | |||
| f) | Place of the transaction | New York Stock Exchange (XNYS) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr R Connor | |||
| b) | Position/status | President, Vaccines and Global Health | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£13.2260 | 230 | ||||
£13.2260 | 133 | ||||
£13.2260 | 154 | ||||
| d) | Aggregated information | ||||
Aggregated volume Price | 517 £13.2260 | ||||
| e) | Date of the transaction | 2022-10-10 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Ms D Conrad | |||
| b) | Position/status | Chief People Officer | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £13.2260 | 94 | ||||
| £13.2260 | 88 | ||||
| £13.2260 | 142 | ||||
| d) | Aggregated information | ||||
Aggregated volume Price | 324 £13.2260 | ||||
| e) | Date of the transaction | 2022-10-10 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr J Ford | |||
| b) | Position/status | SVP and Group General Counsel, Legal and Compliance | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £13.2260 | 135 | ||||
| £13.2260 | 106 | ||||
| £13.2260 | 175 | ||||
| d) | Aggregated information | ||||
Aggregated volume Price | 416 £13.2260 | ||||
| e) | Date of the transaction | 2022-10-10 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Ms S Jackson | |||
| b) | Position/status | SVP, Global Communications and CEO Office | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £13.2260 | 57 | ||||
| £13.2260 | 53 | ||||
| £13.2260 | 81 | ||||
| d) | Aggregated information | ||||
Aggregated volume Price | 191 £13.2260 | ||||
| e) | Date of the transaction | 2022-10-10 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr L Miels | |||
| b) | Position/status | Chief Commercial Officer | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £13.2260 | 220 | ||||
| £13.2260 | 164 | ||||
| £13.2260 | 298 | ||||
| d) | Aggregated information | ||||
Aggregated volume Price | 682 £13.2260 | ||||
| e) | Date of the transaction | 2022-10-10 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Ms S Ramakrishnan | |||
| b) | Position/status | Chief Digital and Technology Officer | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W2044 | |||
| b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 6 October 2022 on ADSs held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| $30.0000 | 30 | ||||
| d) | Aggregated information | N/A (single transaction) | |||
Aggregated volume Price | |||||
| e) | Date of the transaction | 2022-10-10 | |||
| f) | Place of the transaction | New York Stock Exchange (XNYS) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr D Redfern | |||
| b) | Position/status | President Corporate Development | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £13.2260 | 161 | ||||
£13.2260 | 129 | ||||
£13.2260 | 198 | ||||
| d) | Aggregated information | ||||
Aggregated volume Price | 488 £13.2260 | ||||
| e) | Date of the transaction | 2022-10-10 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr R Simard | |||
| b) | Position/status | President, Global Supply Chain | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £13.2260 | 114 | ||||
| £13.2260 | 97 | ||||
| £13.2260 | 179 | ||||
| d) | Aggregated information | ||||
Aggregated volume Price | 390 £13.2260 | ||||
| e) | Date of the transaction | 2022-10-10 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Mr P Thomson | |||
| b) | Position/status | President, Global Affairs | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £13.2260 | 93 | ||||
| £13.2260 | 75 | ||||
| £13.2260 | 124 | ||||
| d) | Aggregated information | ||||
Aggregated volume Price | 292 £13.2260 | ||||
| e) | Date of the transaction | 2022-10-10 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
| 1. | Details of PDMR/person closely associated with them ('PCA') | ||||
| a) | Name | Ms D Waterhouse | |||
| b) | Position/status | CEO, ViiV Healthcare | |||
| c) | Initial notification/amendment | Initial notification | |||
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | GSK plc | |||
| b) | LEI | 5493000HZTVUYLO1D793 | |||
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
| a) | Description of the financial instrument | Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63 | |||
| b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan | |||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
| £13.2260 | 155 | ||||
| £13.2260 | 131 | ||||
| d) | Aggregated information | ||||
Aggregated volume Price | 286 £13.2260 | ||||
| e) | Date of the transaction | 2022-10-10 | |||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| GSK plc | |
| (Registrant) | |
| Date: October 13, 2022 | |
By:/s/ VICTORIA WHYTE -------------------------- | |
| Victoria Whyte | |
| Authorised Signatory for and on | |
| behalf of GSK plc |